Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bioproperties pty. ltd. - herpes virus of turkeys (hvt) strain fc 126 - misc. vaccines or anti sera - herpes virus of turkeys (hvt) strain fc 126 vaccine-viral active 4000.0 pfu/dose - immunotherapy - embryonated chicken egg | poultry chicks | chickens | day old chicks | hatchlings - marek's disease | herpes virus of turkeys (hvt)

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bioproperties pty. ltd. - marek's disease virus strain sb-1 (serotype 2); herpes virus of turkeys strain fc126 (serotype 3)living, - misc. vaccines or anti sera - marek's disease virus strain sb-1 (serotype 2) vaccine-viral active 0.0 pfu/dose; herpes virus of turkeys strain fc126 (serotype 3)living, vaccine-viral active 0.0 pfu/dose - immunotherapy - poultry | breeders | broiler | chickens | chicks | chooks | day old chicks | hatchlings | layers - marek's disease | herpes virus of turkeys (hvt)

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bioproperties pty. ltd. - marek's disease - misc. vaccines or anti sera - marek's disease vaccine-general active 0.0 p - immunotherapy - poultry | breeders | broiler | chickens | chicks | chooks | day old chicks | hatchlings | layers - vaccine | equine rotavirus

Ireland - English - HPRA (Health Products Regulatory Authority)

intervet ireland limited - live chicken herpes virus, strain cvi 988 (serotype1), live turkey herpes virus, strain fc 126 (serotype3) - concentrate for soln for inj - pfu - avian herpes virus vaccine (mareks disease) - fowl - chicken - immunological - live vaccine

Kenya - English - Pharmacy and Poisons Board

ravian lifesciences pvt ltd india - ondasterob - tablet - ondasterob 8mg - antiemetics and antinauseants

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - avian encephalomyelitis virus (live) - misc. vaccines or anti sera - avian encephalomyelitis virus (live) vaccine-viral active 0.0 u - immunotherapy - cage birds | poultry | breeders | broiler | chickens | chicks | chooks | day old chicks | hatchlings | layers - avian encephalomyelitis

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - avian encephalomyelitis virus (i strain) - misc. vaccines or anti sera - avian encephalomyelitis virus (i strain) vaccine-viral active 0.0 p - immunotherapy - poultry pullets (growing chook) | breeding pullets | chickens | growing chooks | immature chooks | laying pullets | young chooks - avian encephalomyelitis

United Kingdom - English - VMD (Veterinary Medicines Directorate)

ceva animal health ltd - turkey herpesvirus - suspension for injection - live viral vaccine - chickens

United States - English - NLM (National Library of Medicine)

biomarin pharmaceutical inc. - valoctocogene roxaparvovec (unii: 681k1jdi8m) (valoctocogene roxaparvovec - unii:681k1jdi8m) - roctavian is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with severe hemophilia a (congenital factor viii deficiency with factor viii activity < 1 iu/dl) without antibodies to adeno-associated virus serotype 5 (aav5) detected by an fda-approved test. administration of roctavian is contraindicated in: - patients with active infections, either acute (such as acute respiratory infections or acute hepatitis) or uncontrolled chronic (such as chronic active hepatitis b). - patients with known significant hepatic fibrosis (stage 3 or 4 on the batts-ludwig scale or equivalent), or cirrhosis [see dosage and administration (2)]. - patients with known hypersensitivity to mannitol. risk summary roctavian is not intended for administration in women. there are no data on the use of roctavian in pregnant women to inform a drug-associated risk of adverse developmental outcome. animal reproduction and developmental toxicity studies have not been conducted with roctavian. it is not known whether roctavian can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the us general population, the estimated background risk of major birth defects occurs in 2 to 4% of the general population and miscarriage occurs in 15 to 20% of clinically recognized pregnancies. risk summary roctavian is not intended for administration in women. there is no information regarding the presence of roctavian in human milk, the effects on the breastfed infant, or the effects on milk production. roctavian is not intended for administration in women. contraception after administration to males in clinical studies, after administration of roctavian, transgene dna was detectable in semen [see clinical pharmacology (12.3)] . in nonclinical studies in healthy mice, the vector dna was detected in the testes for at least 182 days post-administration of roctavian at a dose level of 2.1 × 1014 vg/kg [see clinical pharmacology (12.3)]. in a mating study in immune-deficient mice, roctavian was not detected in liver tissues of offspring of naïve females mated with dosed males [see nonclinical toxicology (13.1)]. for 6 months after administration of roctavian - men of reproductive potential and their female partners must prevent or postpone pregnancy using an effective form of contraception, and - men must not donate semen. the safety and effectiveness of roctavian in pediatric patients have not been established. a single patient ≥ 65 years of age was treated with rocatvian in clinical studies. clinical studies of roctavian did not include sufficient numbers of patients aged 65 and over to determine whether the efficacy or safety differs compared to younger patients. in clinical studies, 3 hiv infected patients have been treated with roctavian. clinical studies of roctavian did not include sufficient numbers of patients with hiv to determine whether the efficacy and safety differs compared to patients without hiv infection. a single hiv infected patient treated with roctavian developed hepatocellular injury that subsequently resolved and was attributed to concomitant administration with antiretroviral drug efavirenz [see drug interactions (7.2)] . the safety and effectiveness of roctavian in patients with prior or active factor viii inhibitors have not been established [see clinical pharmacology (12.6)] . patients with active factor viii inhibitors should not take roctavian. after administration of roctavian, patients should be monitored for the development of factor viii inhibitors by appropriate clinical observations and laboratory tests [see warnings and precautions (5.4)] . the safety and effectiveness of roctavian in patients with hepatic impairment has not been established. clinical studies excluded patients with known hepatic cirrhosis, significant fibrosis (stage 3 or 4 on the batts-ludwig scale or equivalent), current hepatitis b or c, or history of hepatic malignancy. no dose adjustments can be recommended for patients with hepatic impairment. the safety and effectiveness of roctavian in patients with renal impairment has not been established. no dose adjustments can be recommended for patients with renal impairment.

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.1 mg - aviane (levonorgestrel and ethinyl estradiol tablets) is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table 2  lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and norplant® system, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. % of women experiencing an unintended pregnancy within the first year of use % of women continuing use at one year 3 method (1) typical use 1 (2) perfect use 2 (3) (4) chance 4 85 85 spermicides 5 26 6 40 periodic abstinence 25 63      calendar 9      ovulation method 3      sympto-thermal 6 2      post-ovulation 1 cap 7      parous women 40 26 42      nulliparous women 20 9 56 sponge      parous women 40 20 42      nulliparous women 20 9 56